MCID: LYM022
MIFTS: 58

Lymphangioma

Categories: Cancer diseases, Cardiovascular diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphangioma

Summaries for Lymphangioma

GARD: 19 Lymphatic malformations or lymphangiomas are benign (non-cancerous) vascular lesions made of fluid-filled spaces (cysts) thought to occur due to abnormal development of the lymphatic system. In general, Lymphatic malformations are categorized into macrocystic, microcystic, or combined depending on the size of the cysts; they are also classified in superficial lesions known as lymphangioma circumscriptum, and more deep-seated lesions (cavernous lymphangioma and cystic hygroma). They are present at birth, although they may be discovered later in life. They are most commonly located in the neck and axilla, but they also occur in the mouth, arm, mediastinum, lung, leg, abdomen and viscera. Some may appear as a tiny blue or red spot while others are massive and affect an entire arm or leg. The signs and symptoms vary depending on the size and location of the mass; however, lymphangiomas can disfigure affected areas and disrupt the function of nearby organs or tissues. The exact underlying cause is unknown.

MalaCards based summary: Lymphangioma, also known as lymphatic malformation, is related to cystic lymphangioma and capillary lymphangioma. An important gene associated with Lymphangioma is CELSR1 (Cadherin EGF LAG Seven-Pass G-Type Receptor 1), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Sirolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, tongue and adrenal gland, and related phenotypes are Increased cell migration and homeostasis/metabolism

Disease Ontology: 11 A benign vascular tumor that is composed of dilated lymphatic channels.

Wikipedia: 75 Lymphangiomas are malformations of the lymphatic system characterized by lesions that are thin-walled... more...

Related Diseases for Lymphangioma

Diseases related to Lymphangioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 766)
# Related Disease Score Top Affiliating Genes
1 cystic lymphangioma 33.2 PROX1 PECAM1 PDPN FLT4 CD34
2 capillary lymphangioma 33.2 PROX1 PECAM1 PDPN LYVE1 FLT4 CD34
3 colonic lymphangioma 32.7 PECAM1 PDPN CD34
4 lymphangiectasis 31.5 VIM ACTC1
5 hemangioma 31.5 VIM VEGFC VEGFA PROX1 PECAM1 PDPN
6 hereditary lymphedema i 31.2 VEGFC PROX1 PDPN NRP2 LYVE1 FLT4
7 cavernous hemangioma 31.2 VEGFA PECAM1 KDR CD34
8 kaposi sarcoma 31.2 VEGFC VEGFA PECAM1 PDPN LYVE1 KDR
9 intussusception 31.2 VEGFA PECAM1 KDR CD34
10 sarcoma 31.1 VIM PIK3CA KDR FLT4 BRAF ACTC1
11 hydrocele 31.0 VEGFA PECAM1 FLT4
12 klippel-trenaunay-weber syndrome 31.0 VEGFA PROX1 PIK3CA PECAM1 FLT4
13 vascular cancer 31.0 VEGFA PECAM1 KDR FLT4 CD34
14 hemangioendothelioma 30.9 FLT4 CD34
15 spindle cell hemangioma 30.8 PROX1 PECAM1 CD34
16 angiosarcoma 30.8 VIM VEGFC VEGFA PECAM1 PDPN KDR
17 lymphangiosarcoma 30.8 VEGFA PROX1 PECAM1 PDPN LYVE1 FLT4
18 gorham's disease 30.8 VEGFC VEGFA PROX1 PIK3CA PECAM1 PDPN
19 lipomatosis, multiple 30.8 PIK3CA PECAM1 CD34
20 primary lymphedema 30.7 VEGFC FLT4 CELSR1
21 arteriovenous malformation 30.7 VEGFA PECAM1 KDR CD34 BRAF
22 pancreatic cancer 30.7 VIM VEGFC VEGFA PIK3CA PECAM1 MIR143
23 congenital lymphedema 30.7 VEGFC PDPN FLT4
24 gallbladder disease 30.7 VEGFA PDPN MIR143 EGFR
25 capillary hemangioma 30.6 VEGFA PROX1 PECAM1 KDR FLT4 CD34
26 lymphangioleiomyomatosis 30.6 VEGFC VEGFA PDPN EGFR
27 cystadenocarcinoma 30.6 VIM VEGFC VEGFA PDPN AREG ACTC1
28 pneumothorax 30.6 VIM KDR ACTC1
29 hereditary lymphedema 30.6 VEGFC PROX1 PIK3CA PDPN NRP2 LYVE1
30 glomus tumor 30.5 VIM CD34 ACTC1
31 rhabdomyosarcoma 30.5 VIM VEGFA PIK3CA KDR EGFR ACTC1
32 lymphangitis 30.5 VEGFC PDPN LYVE1 FLT4 EGFR
33 hobnail hemangioma 30.5 PECAM1 PDPN FLT4 CD34
34 leiomyosarcoma 30.5 VIM VEGFA PECAM1 ACTC1
35 angiokeratoma circumscriptum 30.5 VEGFA PECAM1 KDR CD34
36 arteriovenous malformations of the brain 30.5 VEGFA PECAM1 KDR EGFR BRAF
37 liposarcoma 30.5 VIM VEGFA PIK3CA CD34
38 neurofibroma 30.4 VIM VEGFA PDPN EGFR CD34 ACTC1
39 adenocarcinoma 30.4 VEGFC VEGFA PIK3CA KDR FLT4 EGFR
40 rapidly involuting congenital hemangioma 30.4 PECAM1 FLT4
41 fibrosarcoma 30.4 VIM KDR EGFR ACTC1
42 neurilemmoma 30.4 VIM CD34 ACTC1
43 rectum adenocarcinoma 30.4 PIK3CA MIR143 EGFR
44 pyogenic granuloma 30.4 VEGFA PECAM1 LYVE1 FLT4 CD34 ACTC1
45 bladder cancer 30.3 VEGFC VEGFA PIK3CA MIR143 KDR EGFR
46 chylothorax, congenital 30.3 VEGFC FLT4
47 endometrial cancer 30.3 VEGFC VEGFA PIK3CA KDR EGFR BRAF
48 breast cancer 30.3 VIM VEGFC VEGFA PIK3CA PECAM1 PDPN
49 skin disease 30.3 VEGFA PIK3CA PECAM1 MIR18A IFNG EGFR
50 inflammatory breast carcinoma 30.3 VEGFC PROX1 LYVE1 EGFR

Comorbidity relations with Lymphangioma via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Lymphangioma:



Diseases related to Lymphangioma

Symptoms & Phenotypes for Lymphangioma

GenomeRNAi Phenotypes related to Lymphangioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell migration GR00055-A-1 9.23 KDR VEGFC
2 Increased cell migration GR00055-A-3 9.23 KDR VEGFC

MGI Mouse Phenotypes related to Lymphangioma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.47 ACTC1 AREG BRAF CD34 EGFR FLT4
2 muscle MP:0005369 10.37 ACTC1 BRAF EGFR FLT4 IFNG KDR
3 cardiovascular system MP:0005385 10.36 ACTC1 AREG BRAF EGFR FLT4 IFNG
4 growth/size/body region MP:0005378 10.34 ACTC1 AREG BRAF CELSR1 EGFR FLT4
5 immune system MP:0005387 10.33 AREG BRAF CD34 CELSR1 EGFR FLT4
6 cellular MP:0005384 10.3 ACTC1 BRAF CD34 CELSR1 EGFR IFNG
7 normal MP:0002873 10.27 ACTC1 BRAF EGFR FLT4 IFNG KDR
8 embryo MP:0005380 10.21 BRAF CELSR1 EGFR FLT4 IFNG KDR
9 digestive/alimentary MP:0005381 10.19 AREG BRAF EGFR FLT4 IFNG PDPN
10 liver/biliary system MP:0005370 10.15 BRAF EGFR FLT4 IFNG KDR PECAM1
11 no phenotypic analysis MP:0003012 10.11 EGFR FLT4 IFNG KDR NRP2 PIK3CA
12 respiratory system MP:0005388 10.11 BRAF CELSR1 EGFR IFNG KDR NRP2
13 craniofacial MP:0005382 10.02 BRAF CELSR1 EGFR IFNG KDR NRP2
14 reproductive system MP:0005389 10.02 AREG BRAF CELSR1 EGFR FLT4 IFNG
15 vision/eye MP:0005391 10 AREG BRAF CELSR1 EGFR IFNG KDR
16 hematopoietic system MP:0005397 10 ACTC1 AREG BRAF CD34 CELSR1 EGFR
17 mortality/aging MP:0010768 9.83 ACTC1 AREG BRAF CELSR1 EGFR FLT4
18 integument MP:0010771 9.4 AREG BRAF CD34 CELSR1 EGFR FLT4

Drugs & Therapeutics for Lymphangioma

Drugs for Lymphangioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
6 Anti-Bacterial Agents Phase 4
7 Anti-Infective Agents Phase 4
8 Antifungal Agents Phase 4
9 Antibiotics, Antitubercular Phase 4
10 Immunosuppressive Agents Phase 4
11 Immunologic Factors Phase 4
12 Picibanil Phase 2, Phase 3
13
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2 23431961
14
Sildenafil Approved, Investigational Phase 1, Phase 2 139755-83-2, 171599-83-0 5212 135398744
15
Citric acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 77-92-9 311
16 Phosphodiesterase Inhibitors Phase 1, Phase 2
17 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
18 Vasodilator Agents Phase 1, Phase 2
19 Citrate Phase 1, Phase 2
20
Selenium Approved, Investigational, Vet_approved Phase 1 7783-07-5, 7782-49-2 533
21 Trace Elements Phase 1
22 Antioxidants Phase 1
23 Micronutrients Phase 1
24 Protective Agents Phase 1

Interventional clinical trials:

(show all 21)
# Name Status NCT ID Phase Drugs
1 Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies: a Randomized Controlled Trial Recruiting NCT04921722 Phase 4 Percutaneous sirolimus;Oral sirolimus
2 Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial Completed NCT00010452 Phase 2, Phase 3 picibanil
3 A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies Unknown status NCT00975819 Phase 2 sirolimus
4 An Investigational Pilot Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations Completed NCT01290484 Phase 1, Phase 2 Sildenafil
5 A Phase 2, Multicenter, Open Label Study to Evaluate the Efficacy and Safety of OK-432 Immunotherapy in Individuals With Lymphatic Malformations Completed NCT03427619 Phase 2 OK432
6 Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations Completed NCT02335242 Phase 2 Sildenafil 20 mg tablets
7 TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN Recruiting NCT04128722 Phase 2 Sirolimus Oral Liquid Product 1mg/mL
8 A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations Recruiting NCT05050149 Phase 2 PTX-022
9 Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis Recruiting NCT03243019 Phase 2 rapamycin
10 Weekly Sirolimus Therapy for the Treatment of Venous and Lymphatic Malformations Recruiting NCT04861064 Phase 2 Sirolimus
11 0.1% Topical Sirolimus in the Treatment of Cutaneous Microcystic Lymphatic Malformations in Children and Adults: Phase II, Split-body Randomized, Double-blind, Vehicle-controlled Clinical Trial Recruiting NCT03972592 Phase 2 Topical 0.1% Sirolimus;Topical Vehicle
12 Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations Terminated NCT04409145 Phase 1, Phase 2 VT30
13 Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc. Recruiting NCT04273334 Phase 1 68Ga-NEB
14 Pilot Clinical Trial to Estimate the Safety and Efficacy of Selenium in the Treatment of Complicated Lymphatic Malformations in Adolescents and Young Adults Terminated NCT01212965 Phase 1 Selenium
15 A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations Withdrawn NCT04994002 Phase 1 CERC-006
16 Airway Vascular Lesions Completed NCT00866827
17 Diagnosis of Hemangiomas and Vascular Malformations Using Non-invasive Imaging Devices Completed NCT00577213
18 Validation of Core Biopsy of Vascular Anomalies for Clinical Pathology and Genomics Completed NCT04836884
19 Lymphatic Anomalies Registry for the Assessment of Outcome Data Recruiting NCT02399527
20 INST UNM 1601: Compassionate Use of BYL 719 Alpelisib Available NCT03941782 Alpelisib
21 Evaluation Nationale Des Enfants et Adultes Avec Syndromes d'Hypercroissance Dysharmonieuse National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Not yet recruiting NCT05563831

Search NIH Clinical Center for Lymphangioma

Cochrane evidence based reviews: lymphangioma

Genetic Tests for Lymphangioma

Genetic tests related to Lymphangioma:

# Genetic test Affiliating Genes
1 Lymphangioma 28
2 Lymphatic Malformation 28

Anatomical Context for Lymphangioma

Organs/tissues related to Lymphangioma:

MalaCards : Lung, Tongue, Adrenal Gland, Small Intestine, Pancreas, Spleen, Colon

Publications for Lymphangioma

Articles related to Lymphangioma:

(show top 50) (show all 5774)
# Title Authors PMID Year
1
Genotype correlates with clinical severity in PIK3CA-associated lymphatic malformations. 62 5
31536475 2019
2
PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations. 62 5
29985963 2018
3
Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. 62 5
25681199 2015
4
PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution. 5
27631024 2016
5
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. 5
15608678 2005
6
VEGF-C and VEGFR-3 in a series of lymphangiomas: is superficial lymphangioma a true lymphangioma? 53 62
19151999 2009
7
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. 53 62
17584927 2007
8
Podoplanin: a novel diagnostic immunohistochemical marker. 53 62
16670463 2006
9
Expression of a lymphatic endothelial cell marker in benign and malignant vascular tumors. 53 62
15257549 2004
10
CD9 expression on lymphatic vessels in head and neck mucosa. 53 62
14559986 2003
11
The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. 53 62
12060670 2002
12
Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. 53 62
11742043 2001
13
Orbital lymphangioma with positive immunohistochemistry of lymphatic endothelial markers (vascular endothelial growth factor receptor 3 and podoplanin). 53 62
11585321 2001
14
Lymphangioma of large intestine: report of ten cases with endoscopic and pathologic correlation. 53 62
10922105 2000
15
Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. 53 62
10931742 2000
16
Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas. 53 62
10697276 2000
17
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. 53 62
10590384 1999
18
Immunoelectron microscopic characterization of human dermal lymphatic microvascular endothelial cells. Differential expression of CD31, CD34, and type IV collagen with lymphatic endothelial cells vs blood capillary endothelial cells in normal human skin, lymphangioma, and hemangioma in situ. 53 62
9446823 1998
19
Mesentric lymphatic malformation presented with a small bowel internal hernia: A case report. 62
36340227 2023
20
A fetus with large mediastinal cystic lymphatic malformation managed with prenatal serial thoracocentesis and postnatal sclerotherapy. 62
36164802 2022
21
Lymphatic/Blood Vessel Plasticity: Motivation for a Future Research Area Based on Present and Past Observations. 62
36459445 2022
22
Comprehensive targeted next-generation sequencing in patients with slow-flow vascular malformations. 62
36171295 2022
23
Successful treatment with MEK-inhibitor in a patient with NRAS-related cutaneous skeletal hypophosphatemia syndrome. 62
35999193 2022
24
Hyperphosphatemic familial tumoral calcinosis mimicking a cystic hemo-lymphangioma on MRI. 62
36193273 2022
25
Perinatal presentations of non-immune hydrops fetalis due to recessive PIEZO1 disease: a challenging fetal diagnosis. 62
36453701 2022
26
Diagnosis of splenic cavernous lymphangioma by CT and multimodal MRI: a comparative analysis of imaging and pathology. 62
36468694 2022
27
Right Ventricular Epicardium-Originated Cardiac Lymphangioma: A Rare Tumor and Rare Origin. 62
35216993 2022
28
Trifoliate mesenteric lymphatic malformation. 62
35840486 2022
29
The VASCERN-VASCA working group diagnostic and management pathways for lymphatic malformations. 62
36223836 2022
30
Institutional Management of Abdominal Lymphatic Malformations: Evolution of Treatment Over a Decade. 62
36030605 2022
31
Paediatric lymphoedema: An audit of patients seen by the paediatric and primary lymphoedema group of vascular European Reference Network (VASCERN). 62
36243335 2022
32
Lymphatic malformations in children: retrospective review of surgical and interventional management. 62
36469112 2022
33
Long-term outcomes of lymphatic malformations in children: An 11-year experience from a tertiary referral center. 62
35973860 2022
34
Alpelisib for the treatment of PIK3CA-related head and neck lymphatic malformations and overgrowth. 62
36066547 2022
35
Primary targeted medical therapy for management of bilateral head and neck lymphatic malformations in infants. 62
36459725 2022
36
Extremely Rare Case of Cavernous Haemangioma of Submandibular Gland. 62
36474490 2022
37
Curettage and sclerotherapy technique: A hybrid approach to superficial lymphatic malformation. 62
36444750 2022
38
Sirolimus-induced pulmonary hemorrhage of an infant with massive cervicofacial lymphatic malformation: A case report. 62
36469963 2022
39
Condyloma acuminata mimicking cutaneous microcystic lymphatic malformation. 62
33666056 2022
40
Treatment With Topical Sirolimus for Recurrent Lymphatic Malformation of the External Urethral Meatus. 62
36044195 2022
41
A lymphatic malformation with a "Lympholith" and encasing neurovascular structures in the arm of a 2-year-old child: A case report. 62
36415720 2022
42
Fetal Cervical Lymphangioma: Magnetic Resonance Imaging and Three-Dimensional Reconstruction Modelling. 62
34308843 2022
43
Rare finding of duodenal lymphangioma in a patient with Helicobacter pylori associated gastritis: A case report. 62
36451462 2022
44
Mesenteric ruptured lymphangioma mimicking acute appendicitis. 62
36427220 2022
45
Review of diagnosis, differential diagnosis, and management of retroperitoneal lymphangioma. 62
36327088 2022
46
A Rare Case of Cystic Lymphangioma Involving the Fallopian Tube. 62
35908597 2022
47
Nevus Lipomatosus Superficialis in a Serous Inflammatory Capsule: A Case Report. 62
36352757 2022
48
Microcystic lymphatic malformation presenting as firm, skin-colored papules of the lips. 62
35739629 2022
49
[Incidental finding of a Müllerian cyst in an exceptional retroperitoneal localization]. 62
35314077 2022
50
Laparoscopy ıs a defınıtıve dıagnostıc method for auto-amputated ovary ın ınfants. 62
35964259 2022

Variations for Lymphangioma

ClinVar genetic disease variations for Lymphangioma:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PIK3CA NM_006218.4(PIK3CA):c.3202_3205delinsCTGATAACTGAGAAAATAACTGATAAAATGAAACTGA (p.Asn1068_Ter1069delinsLeuIleThrGluLysIleThrAspLysMetLysLeuArg) INDEL Pathogenic
1177432 GRCh37: 3:178952147-178952150
GRCh38: 3:179234359-179234362
2 CELSR1 NM_001378328.1(CELSR1):c.5226+2T>A SNV Pathogenic
598932 rs1569141899 GRCh37: 22:46804891-46804891
GRCh38: 22:46408994-46408994
3 CELSR1 NM_001378328.1(CELSR1):c.6739+1G>A SNV Pathogenic
598933 rs1569124017 GRCh37: 22:46782298-46782298
GRCh38: 22:46386401-46386401
4 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
5 CELSR1 NM_001378328.1(CELSR1):c.868G>T (p.Glu290Ter) SNV Likely Pathogenic
590904 rs1569227576 GRCh37: 22:46932200-46932200
GRCh38: 22:46536303-46536303
6 CELSR1 NM_001378328.1(CELSR1):c.5702-1G>C SNV Likely Pathogenic
598923 rs1569133268 GRCh37: 22:46792644-46792644
GRCh38: 22:46396747-46396747
7 CELSR1 NM_001378328.1(CELSR1):c.2042del (p.Asn681fs) DEL Likely Pathogenic
598924 rs1569226110 GRCh37: 22:46931026-46931026
GRCh38: 22:46535129-46535129

Expression for Lymphangioma

Search GEO for disease gene expression data for Lymphangioma.

Pathways for Lymphangioma

Pathways related to Lymphangioma according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 VIM VEGFC VEGFA NRP2 KDR FLT4
2 13.73 VIM VEGFC VEGFA PIK3CA NRP2 KDR
3
Show member pathways
13.7 VEGFC VEGFA NRP2 KDR FLT4 EGFR
4
Show member pathways
13.53 VEGFC VEGFA PIK3CA KDR IFNG FLT4
5
Show member pathways
13.24 VIM VEGFC VEGFA KDR FLT4 EGFR
6
Show member pathways
13.06 VEGFC NRP2 KDR FLT4 EGFR AREG
7
Show member pathways
13.04 VEGFC NRP2 KDR FLT4 EGFR BRAF
8
Show member pathways
12.95 VEGFC VEGFA PIK3CA KDR FLT4 EGFR
9
Show member pathways
12.71 BRAF EGFR KDR PIK3CA VEGFA
10
Show member pathways
12.71 AREG EGFR FLT4 KDR VEGFC
11
Show member pathways
12.54 VEGFC PIK3CA NRP2 KDR IFNG FLT4
12
Show member pathways
12.5 PIK3CA EGFR BRAF AREG
13 12.47 VEGFC VEGFA PIK3CA KDR FLT4 EGFR
14
Show member pathways
12.45 PIK3CA FLT4 EGFR BRAF
15
Show member pathways
12.43 EGFR FLT4 KDR PIK3CA
16
Show member pathways
12.4 VEGFC VEGFA KDR FLT4 EGFR
17
Show member pathways
12.38 VEGFA PIK3CA NRP2 KDR BRAF
18
Show member pathways
12.34 VEGFC VEGFA PIK3CA NRP2 KDR FLT4
19 12.33 VEGFC VEGFA PIK3CA NRP2 KDR FLT4
20
Show member pathways
12.32 AREG BRAF EGFR FLT4 KDR PIK3CA
21
Show member pathways
12.27 VEGFC VEGFA PIK3CA NRP2 KDR FLT4
22 12.25 PIK3CA KDR FLT4 EGFR
23 12.23 VEGFC VEGFA PIK3CA KDR EGFR BRAF
24
Show member pathways
12.22 PIK3CA KDR FLT4 EGFR BRAF
25 12.19 VEGFA IFNG EGFR BRAF
26
Show member pathways
12.19 VEGFC VEGFA KDR EGFR AREG
27 12.14 VEGFC KDR FLT4 EGFR
28 12.1 KDR FLT4 EGFR BRAF
29 12.08 VIM VEGFA PROX1 KDR
30
Show member pathways
11.89 PIK3CA EGFR AREG
31 11.88 VIM VEGFC VEGFA
32 11.86 VIM VEGFA IFNG
33
Show member pathways
11.85 KDR FLT4 EGFR
34 11.82 VEGFA KDR EGFR
35
Show member pathways
11.78 BRAF FLT4 KDR PIK3CA
36 11.74 VEGFA PIK3CA EGFR
37 11.67 VEGFA PIK3CA KDR BRAF
38 11.63 VEGFA PIK3CA KDR
39 11.6 IFNG EGFR CD34
40 11.57 VEGFA PECAM1 KDR EGFR
41 11.55 VEGFA PIK3CA KDR
42 11.52 VEGFC VEGFA MIR143
43
Show member pathways
11.48 VEGFA PIK3CA KDR EGFR
44 11.45 VEGFA PIK3CA KDR IFNG EGFR
45 11.44 BRAF EGFR VEGFA
46 11.43 VEGFA PECAM1 KDR
47 11.24 BRAF EGFR PIK3CA
48 11.24 IFNG VEGFA VEGFC
49 11.2 VEGFA PIK3CA NRP2
50 11.19 VEGFA KDR FLT4 EGFR BRAF

GO Terms for Lymphangioma

Cellular components related to Lymphangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.7 PECAM1 PDPN NRP2 LYVE1 KDR FLT4
2 plasma membrane GO:0005887 9.7 PECAM1 PDPN NRP2 LYVE1 KDR FLT4

Biological processes related to Lymphangioma according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.41 VIM VEGFA IFNG CD34 BRAF ACTC1
2 negative regulation of apoptotic process GO:0043066 10.41 VEGFA PDPN KDR FLT4 EGFR BRAF
3 negative regulation of gene expression GO:0010629 10.36 VEGFA PIK3CA KDR IFNG CD34
4 positive regulation of cell population proliferation GO:0008284 10.36 VEGFC VEGFA PROX1 KDR IFNG FLT4
5 angiogenesis GO:0001525 10.28 VEGFC VEGFA PIK3CA NRP2 KDR FLT4
6 cell-cell adhesion GO:0098609 10.27 PECAM1 PDPN EGFR CELSR1 CD34
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.26 VEGFA KDR FLT4 EGFR BRAF
8 peptidyl-tyrosine phosphorylation GO:0018108 10.21 KDR FLT4 EGFR BRAF
9 positive regulation of angiogenesis GO:0045766 10.2 CD34 KDR MIR143 VEGFA VEGFC
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.19 BRAF EGFR PIK3CA VEGFA
11 lung development GO:0030324 10.14 VEGFA PROX1 PDPN KDR
12 positive regulation of cell migration GO:0030335 10.13 VEGFC VEGFA PECAM1 PDPN KDR FLT4
13 positive regulation of protein kinase B signaling GO:0051897 10.11 VEGFA PIK3CA MIR143 EGFR
14 epidermal growth factor receptor signaling pathway GO:0007173 10.11 PIK3CA EGFR BRAF AREG
15 sprouting angiogenesis GO:0002040 10.1 VEGFC VEGFA FLT4
16 cellular response to vascular endothelial growth factor stimulus GO:0035924 10.09 VEGFA KDR FLT4
17 positive regulation of endothelial cell migration GO:0010595 10.07 VEGFA PROX1 NRP2 KDR FLT4
18 positive regulation of protein phosphorylation GO:0001934 10.07 BRAF EGFR FLT4 KDR PECAM1 VEGFA
19 positive regulation of epithelial cell proliferation GO:0050679 10.03 VEGFC VEGFA KDR EGFR
20 positive regulation of blood vessel endothelial cell migration GO:0043536 10.02 VEGFC VEGFA MIR143 KDR
21 vascular endothelial growth factor receptor signaling pathway GO:0048010 10.01 FLT4 KDR VEGFA VEGFC
22 lymphangiogenesis GO:0001946 10 PROX1 PDPN FLT4
23 skeletal muscle thin filament assembly GO:0030240 9.96 ACTC1 PROX1
24 positive regulation of mast cell chemotaxis GO:0060754 9.96 VEGFA VEGFC
25 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.95 VEGFA KDR
26 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.94 VEGFA KDR
27 glomerular endothelium development GO:0072011 9.93 PECAM1 CD34
28 positive regulation of endothelial cell proliferation GO:0001938 9.93 VEGFC VEGFA PROX1 NRP2 KDR FLT4
29 blood vessel endothelial cell differentiation GO:0060837 9.92 KDR PROX1
30 vascular wound healing GO:0061042 9.91 VEGFA KDR CD34
31 lymphatic endothelial cell fate commitment GO:0060838 9.9 PROX1 PDPN
32 lymph vessel development GO:0001945 9.89 FLT4 KDR PROX1
33 aorta smooth muscle tissue morphogenesis GO:0060414 9.83 PROX1 MIR143
34 actin-mediated cell contraction GO:0070252 9.79 ACTC1 PDPN
35 positive regulation of phosphorylation GO:0042327 9.43 VEGFA KDR FLT4 EGFR AREG
36 vascular endothelial growth factor signaling pathway GO:0038084 9.4 VEGFC VEGFA PIK3CA NRP2 KDR FLT4

Molecular functions related to Lymphangioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor binding GO:0019838 9.63 NRP2 KDR FLT4
2 vascular endothelial growth factor receptor binding GO:0005172 9.56 VEGFC VEGFA
3 protein tyrosine kinase activity GO:0004713 9.43 KDR FLT4 EGFR BRAF
4 vascular endothelial growth factor receptor activity GO:0005021 9.1 NRP2 KDR FLT4

Sources for Lymphangioma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....